Investigating the effect of probiotics in the treatment of Helicobacter pylori infection

Investigating the effect of probiotic composition on the treatment regimen of four drugs for Helicobacter pylori infection

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20240222061080N1

Enrollment

200

Registered

2024-02-28

Start date

2024-04-03

Completion date

Unknown

Last updated

2024-03-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with Helicobacter pylori infection. Helicobacter pylori [H. pylori] as the cause of diseases classified elsewhere

Interventions

Intervention 1: Intervention group: Oral metronidazole 500 mg four times a day / Oral bismuth 300 mg four times a day / Oral amoxicillin 500 mg four times a day / Oral omeprazole 40 mg twice a day / F

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: Patients with Helicobacter pylori infection Age 18 to 75 years

Exclusion criteria

Exclusion criteria: Gastric cancer Kidney and liver failure History of gastric surgery Pregnancy and breastfeeding Unwillingness to participate in the study

Design outcomes

Primary

Measure	Time frame
The recurrence rate of Helicobacter pylori in patients. Timepoint: 4 weeks after treatment. Method of measurement: Fecal antigen test.	—

Secondary

Measure	Time frame
The incidence of complications and improvement of clinical symptoms in patients. Timepoint: 4 weeks after the end of the intervention. Method of measurement: Clinical examination in terms of pain or burning in the abdomen and the affected area below the ribs and above the navel.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactNajmeh Khalili Naft Chali

Qazvin University of Medical Sciences

najmeh.khalili2016@gmail.com+98 28 3379 0620

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026